Overall Score

Political

Healthcare reimbursement and public-sector procurement remain key external policy sensitivities for Omnicell's hospital automation business.

No new political or regulatory developments were provided this month.

Economic

Valuation remains reasonable at 1.28x EV/Sales and 11.31x EV/FCF, while free cash flow yield is 8.36%.

Liquidity and leverage remain solid with a 1.64 current ratio and net debt to EBITDA of -0.87x.

Profitability is still modest with 3.13% net margin and 2.41% ROIC.

Social

Demand for medication management and workflow automation is supported by labor shortages and hospital efficiency needs.

No new customer adoption or workforce-related developments were provided this month.

Technological

Gross margin remains healthy at 44.8%, suggesting the product mix still supports differentiated technology economics.

R&D intensity is moderate at 7.1% of revenue, indicating continued investment in product development.

No new product launches, platform updates, or technology setbacks were reported this month.

Legal

No new litigation, compliance, or regulatory enforcement items were reported this month.

The business remains exposed to healthcare compliance and product liability requirements.

Environmental

No new environmental, sustainability, or supply-chain disruption news was provided this month.

Capex remains modest at 3.3% of revenue, limiting near-term environmental capital burden.